Top

Published in:

01-09-2009 | Nuclear Medicine

Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development

Authors: Till A. Heusner, Steffen Hahn, Monia E. Hamami, Un-Hi Kim, Rilana Baumeister, Michael Forsting, Alexander Stahl, Andreas Bockisch, Gerald Antoch

Published in: European Radiology | Issue 9/2009

Abstract

Focal gastrointestinal 2-deoxy-2-[¹⁸F]-fluoro-D-glucose (FDG) uptake can frequently be found on FDG-PET/CT even in patients without known gastrointestinal malignancy. The aim of this study was to evaluate whether increased gastrointestinal FDG uptake without CT correlate is an early indicator of patients developing gastrointestinal malignancies. A total of 1,006 patients without esophagogastric or anorectal malignancies underwent FDG-PET/CT. The esophagogastric junction, the stomach and the anorectum were evaluated for increased FDG uptake. Patients without elevated uptake were assigned to group A, patients with elevated uptake were allocated to group B. The SUVmax values of both groups were tested for significant differences using the U test. A follow-up of longer than 1 year (mean 853 ± 414 days) served as gold standard. A total of 460 patients had to be excluded based on insufficient follow-up data. For the remaining 546 patients the mean SUVmax was as follows: (a) esophagogastric junction, group A 3.1 ± 0.66, group B 4.0 ± 1.11, p < 0.01; (b) stomach, group A 2.8 ± 0.77, group B 4.1 ± 1.33, p < 0.01; (c) rectal ampulla, group A 2.8 ± 0.83, group B 3.9 ± 1.49, p < 0.01; (d) anal canal, group A 2.7 ± 0.55, group B 3.9 ± 1.59, p < 0.01. Only one patient developed gastric cancer. In the case of an unremarkable CT, elevated esophagogastric or anorectal FDG uptake does not predict cancer development and does not have to be investigated further.

Townsend DW (2008) Positron emission tomography/computed tomography. Semin Nucl Med 38:152–166PubMedCrossRef

Townsend DW (2008) Multimodality imaging of structure and function. Phys Med Biol 53:R1–R39PubMedCrossRef

Blodgett TM, Meltzer CC, Townsend DW (2007) PET/CT: form and function. Radiology 242:360–385PubMedCrossRef

Antoch G, Vogt FM, Freudenberg LS et al (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290:3199–3206PubMedCrossRef

Antoch G, Saoudi N, Kuehl H et al (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22:4357–4368PubMedCrossRef

Antoch G, Vogt FM, Bockisch A et al (2004) Whole-body tumor staging: MRI or FDG-PET/CT? Radiologe 44:882–888PubMedCrossRef

Antoch G, Kaiser GM, Mueller AB et al (2004) Intraoperative radiation therapy in liver tissue in a pig model: monitoring with dual-modality PET/CT. Radiology 230:753–760PubMedCrossRef

Stahl A, Ott K, Weber WA et al (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288–295PubMed

Stahl A, Weber WA, Avril N et al (2000) Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin 39:241–245PubMed

10.

Wahl RL, Kaminski MS, Ethier SP et al (1990) The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 31:1831–1835PubMed

11.

Kamel EM, Thumshirn M, Truninger K et al (2004) Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 45:1804–1810PubMed

12.

Rosenbaum SJ, Lind T, Antoch G et al (2006) False-positive FDG PET uptake—the role of PET/CT. Eur Radiol 16:1054–1065PubMedCrossRef

13.

Wahl RL (1996) Targeting glucose transporters for tumor imaging: “sweet” idea, “sour” result. J Nucl Med 37:1038–1041PubMed

14.

Abouzied MM, Crawford ES, Nabi HA (2005) 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 33:145–55PubMed

15.

Prabhakar HB, Sahani DV, Fischman AJ et al (2007) Bowel hot spots at PET-CT. Radiographics 27:145–159PubMedCrossRef

16.

Cohade C, Osman M, Nakamoto Y et al (2003) Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med 44:412–416PubMed

17.

Antoch G, Kuehl H, Kanja J et al (2004) Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 230:879–885PubMedCrossRef

18.

Beyer T, Antoch G, Blodgett T et al (2003) Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 30:588–596PubMed

19.

Cook GJ, Fogelman I, Maisey MN (1996) Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 26:308–314PubMedCrossRef

20.

Cook GJ, Maisey MN, Fogelman I (1999) Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 26:1363–1378PubMedCrossRef

21.

Fukunaga T, Okazumi S, Koide Y et al (1998) Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 39:1002–1007PubMed

22.

Metser U, Even-Sapir E (2007) Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med 37:206–222PubMedCrossRef

23.

Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61–77PubMed

24.

Salaun PY, Grewal RK, Dodamane I et al (2005) An analysis of the 18F-FDG uptake pattern in the stomach. J Nucl Med 46:48–51PubMed

25.

Stringer AM, Gibson RJ, Bowen JM et al (2007) Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 5:259–267PubMed

26.

Wang Y, Chiu E, Rosenberg J et al (2007) Standardized uptake value atlas: characterization of physiological 2-deoxy-2-[18F]fluoro-D-glucose uptake in normal tissues. Mol Imaging Biol 9:83–90PubMedCrossRef

27.

Zincirkeser S, Sahin E, Halac M et al (2007) Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging. J Int Med Res 35:231–236PubMed

28.

Capirci C, Rampin L, Erba PA et al (2007) Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 34:1583–1593PubMedCrossRef

29.

Cheze-Le Rest C, Metges JP, Teyton P et al (2008) Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study. Nucl Med Commun 29:628–635PubMedCrossRef

30.

Mochiki E, Kuwano H, Katoh H et al (2004) Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 28:247–253PubMedCrossRef

31.

Blecker D, Abraham S, Furth EE et al (1999) Melanoma in the gastrointestinal tract. Am J Gastroenterol 94:3427–3433PubMedCrossRef

32.

Liang KV, Sanderson SO, Nowakowski GS et al (2006) Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc 81:511–516PubMedCrossRef

33.

Schuchter LM, Green R, Fraker D (2000) Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract. Curr Opin Oncol 12:181–185PubMedCrossRef

Title: Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development
Authors: Till A. Heusner
Steffen Hahn
Monia E. Hamami
Un-Hi Kim
Rilana Baumeister
Michael Forsting
Alexander Stahl
Andreas Bockisch
Gerald Antoch
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: European Radiology / Issue 9/2009
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-009-1405-7

At a glance: The STEP trials

Springer Medicine

Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2009

Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging: preliminary findings

Sixty-four-slice multidetector computed tomography for preoperative evaluation of left ventricular function and mass in patients with mitral regurgitation: comparison with magnetic resonance imaging and echocardiography

Atherosclerotic plaque volume and composition in symptomatic carotid arteries assessed with multidetector CT angiography; relationship with severity of stenosis and cardiovascular risk factors

A novel method for contrast-to-noise ratio (CNR) evaluation of digital mammography detectors

Parotid incidentaloma identified by combined 18F-fluorodeoxyglucose whole-body positron emission tomography and computed tomography: findings at grayscale and power Doppler ultrasonography and ultrasound-guided fine-needle aspiration biopsy or core-needle biopsy

Direct magnetic resonance arthrography of the knee: utility of axial traction